Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00343291 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00343291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00343291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
December 31, 2010
Enrollment
121 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer